Telmisartan-d3

• Description:

  Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Angiotensin Receptor; Autophagy

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy; GPCR/G Protein

• Field of Research:

  Cardiovascular Disease; Endocrinology

• Purity:

  99.77

• Solubility:

  10 mM in DMSO|DMF : ≥ 1.6mg/mL|DMSO : ≥ 1mg/mL

• Smiles:

  CC1=CC(C2=NC3=C(N2C([2H])([2H])[2H])C=CC=C3)=CC4=C1N=C(N4CC5=CC=C(C=C5)C6=CC=CC=C6C(O)=O)CCC

• Molecular Formula:

  C33H27D3N4O2

• Molecular Weight:

  517.64

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Maillard MP, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002 Sep;302 (3) :1089-95.|[3]Xuan H, et al. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms. J Vasc Surg. 2017 Apr 20. pii: S0741-5214 (17) 30100-3.|[4]Torika N, et al. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice. Brain Behav Immun. 2017 Apr 3.|[5]Aswar U, et al. Telmisartan attenuates diabetes induced depression in rats. Pharmacol Rep. 2017 Apr;69 (2) :358-364.|[6]Fujihara S, et al. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 2017 Jan 31;8 (5) :8536-8549.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1189889-44-8